DeepMed Research

Tonix Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $7.9M

Website

Clinical Trials

Comparing Efficacy & Safety of TNX-1300 to Placebo with UC for Treatment of Acute Cocaine Intoxication in ED Subjects (CATALYST)

Phase 2

Recruiting

Conditions: Cocaine Use
Cocaine Intoxication
Cocaine Abuse
Cocaine Adverse Reaction
Cocaine Toxicity

Interventions: Drug: TNX-1300 (Injection)
Drug: Placebo (Injection)

First Posted Date: 2023-09-21

Last Posted Date: 2025-03-05

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT06045793

Locations: 🇺🇸
University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States

and more 3 locations

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Depressive Disorder, Major
Depressive Episode
Depression Severe
Depression
Depressive Disorder
Depressive Symptoms

Interventions: Drug: Placebo
Drug: TNX-601 ER

First Posted Date: 2023-01-17

Last Posted Date: 2025-02-17

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 132

Registration Number: NCT05686408

Locations: 🇺🇸
Cenexel Research - Decatur, Decatur, Georgia, United States
🇺🇸
Preferred Research Partners, Little Rock, Arkansas, United States
🇺🇸
Cenexel CIT - Bellflower, Bellflower, California, United States

and more 24 locations

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Phase 2

Completed

Conditions: Chronic Migraine
Chronic Migraine, Headache
Chronic Migraine Without Aura
Aura Migraine

Interventions: Drug: TNX-1900
Drug: Placebo Nasal Spray

First Posted Date: 2023-01-11

Last Posted Date: 2025-02-25

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 88

Registration Number: NCT05679908

Locations: 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States
🇺🇸
Alliance for Multispecialty Research - Wichita West, Wichita, Kansas, United States

and more 21 locations

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Phase 2

Completed

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
COVID-19
Long COVID
Long Haul COVID

Interventions: Drug: TNX-102 SL
Drug: Placebo SL Tablet

First Posted Date: 2022-07-25

Last Posted Date: 2024-11-26

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 63

Registration Number: NCT05472090

Locations: 🇺🇸
Accel Research-Birmingham Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸
Tonix Clinical Site, McKinney, Texas, United States

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

Phase 2

Withdrawn

Conditions: PTSD

Interventions: Drug: TNX-102 SL
Drug: Placebo

First Posted Date: 2022-05-13

Last Posted Date: 2023-12-11

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Registration Number: NCT05372887

Locations: 🇰🇪
Centre for Clinical Research at KEMRI-Nairobi, Nairobi, Kenya
🇰🇪
Aga Khan University Clinical Research Unit, Nairobi, Kenya
🇰🇪
Moi University Clinical Research Centre, Nairobi, Kenya

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia

Interventions: Drug: TNX-102 SL Tablet, 5.6 mg
Drug: Placebo SL Tablet

First Posted Date: 2022-03-10

Last Posted Date: 2025-01-22

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 457

Registration Number: NCT05273749

Locations: 🇺🇸
Tonix Clinical Site, Kenosha, Wisconsin, United States

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Phase 1

Terminated

Conditions: Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Interventions: Biological: TNX-2110
Biological: TNX-2120
Biological: TNX-2130
Biological: CANDIN
Biological: Diluent

First Posted Date: 2022-01-31

Last Posted Date: 2024-11-06

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 9

Registration Number: NCT05216510

Locations: 🇺🇸
Clinical Site, Berlin, New Jersey, United States

An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects

Phase 2

Withdrawn

Conditions: Cocaine Intoxication

Interventions: Other: Usual Care
Drug: TNX-1300

First Posted Date: 2021-08-09

Last Posted Date: 2022-06-29

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Registration Number: NCT04996056

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo SL Tablet
Drug: TNX-102 SL

First Posted Date: 2020-08-11

Last Posted Date: 2023-12-18

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 514

Registration Number: NCT04508621

Locations: 🇺🇸
Tonix Clinical Site, Kenosha, Wisconsin, United States

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia

Interventions: Drug: TNX-102 SL
Drug: Placebo SL Tablet

First Posted Date: 2019-11-21

Last Posted Date: 2022-08-08

Lead Sponsor: Tonix Pharmaceuticals, Inc.

Target Recruit Count: 503

Registration Number: NCT04172831

Locations: 🇺🇸
Tonix Clinical Site, Kenosha, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy